Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

Table 3

Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast.

IGFBP-2 (µIU/mL)	Co/Ca	Model 1 OR^a	Model 2 OR^b	Co/Ca	Model 3 OR^c
Q1 (<149.9)	69/77	1.0^Ref.	1.0^Ref.	63/71	1.0^Ref.
Q2 (150.0–225.4)	69/69	0.86 (0.53–1.39)	1.11 (0.65–1.87)	61/64	1.14 (0.65–1.98)
Q3 (225.5–349.5)	69/78	0.88 (0.55–1.40)	1.09 (0.65–1.84)	66/74	1.03 (0.60–1.78)
Q4 (≥349.6)	68/51	0.51 (0.29–0.90)	0.70 (0.36–1.38)	68/50	0.65 (0.32–1.31)
Trend		0.03	0.27		0.16

Model 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m²).
Model 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
Model 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.